1
|
Di Carluccio C, Soriano-Maldonado P, Berni F, de Haas CJC, Temming AR, Hendriks A, Ali S, Molinaro A, Silipo A, van Sorge NM, van Raaij MJ, Codee JDC, Marchetti R. Antibody Recognition of Different Staphylococcus aureus Wall Teichoic Acid Glycoforms. ACS CENTRAL SCIENCE 2022; 8:1383-1392. [PMID: 36313161 PMCID: PMC9615122 DOI: 10.1021/acscentsci.2c00125] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Indexed: 05/14/2023]
Abstract
Wall teichoic acids (WTAs) are glycopolymers decorating the surface of Gram-positive bacteria and potential targets for antibody-mediated treatments against Staphylococcus aureus, including methicillin-resistant (MRSA) strains. Through a combination of glycan microarray, synthetic chemistry, crystallography, NMR, and computational studies, we unraveled the molecular and structural details of fully defined synthetic WTA fragments recognized by previously described monoclonal antibodies (mAbs 4461 and 4497). Our results unveiled the structural requirements for the discriminatory recognition of α- and β-GlcNAc-modified WTA glycoforms by the complementarity-determining regions (CDRs) of the heavy and light chains of the mAbs. Both mAbs interacted not only with the sugar moiety but also with the phosphate groups as well as residues in the ribitol phosphate (RboP) units of the WTA backbone, highlighting their significant role in ligand specificity. Using elongated WTA fragments, containing two sugar modifications, we also demonstrated that the internal carbohydrate moiety of α-GlcNAc-modified WTA is preferentially accommodated in the binding pocket of mAb 4461 with respect to the terminal moiety. Our results also explained the recently documented cross-reactivity of mAb 4497 for β-1,3/β-1,4-GlcNAc-modified WTA, revealing that the flexibility of the RboP backbone is crucial to allow positioning of both glycans in the antibody binding pocket.
Collapse
Affiliation(s)
- Cristina Di Carluccio
- Department
of Chemical Sciences, University of Naples
Federico II, Via Cinthia 4, 80126Naples, Italy
| | - Pablo Soriano-Maldonado
- Departamento
de Estructura de Macromoléculas, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones
Científicas (CNB-CSIC), Calle Darwin 3, 28049Madrid, Spain
| | - Francesca Berni
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CCLeiden, The Netherlands
| | - Carla J. C. de Haas
- Medical
Microbiology, UMC Utrecht, Utrecht University, 3508Utrecht, The Netherlands
| | - A. Robin Temming
- Department
of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, 1105 AZAmsterdam, The Netherlands
| | - Astrid Hendriks
- Department
of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, 1105 AZAmsterdam, The Netherlands
| | - Sara Ali
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CCLeiden, The Netherlands
| | - Antonio Molinaro
- Department
of Chemical Sciences, University of Naples
Federico II, Via Cinthia 4, 80126Naples, Italy
| | - Alba Silipo
- Department
of Chemical Sciences, University of Naples
Federico II, Via Cinthia 4, 80126Naples, Italy
| | - Nina M. van Sorge
- Department
of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, 1105 AZAmsterdam, The Netherlands
- Netherlands
Reference Laboratory for Bacterial Meningitis, Amsterdam UMC, 1105 AZAmsterdam, The Netherlands
- Email
for N.M.v.S.:
| | - Mark J. van Raaij
- Departamento
de Estructura de Macromoléculas, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones
Científicas (CNB-CSIC), Calle Darwin 3, 28049Madrid, Spain
- Email for M.J.v.R.:
| | - Jeroen D. C. Codee
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CCLeiden, The Netherlands
- Email for J.D.C.C.:
| | - Roberta Marchetti
- Department
of Chemical Sciences, University of Naples
Federico II, Via Cinthia 4, 80126Naples, Italy
- Email for R.M.:
| |
Collapse
|
2
|
Del Bino L, Østerlid KE, Wu DY, Nonne F, Romano MR, Codée J, Adamo R. Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance. Chem Rev 2022; 122:15672-15716. [PMID: 35608633 PMCID: PMC9614730 DOI: 10.1021/acs.chemrev.2c00021] [Citation(s) in RCA: 50] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Antimicrobial resistance (AMR) is emerging as the next potential pandemic. Different microorganisms, including the bacteria Acinetobacter baumannii, Clostridioides difficile, Escherichia coli, Enterococcus faecium, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, non-typhoidal Salmonella, and Staphylococcus aureus, and the fungus Candida auris, have been identified by the WHO and CDC as urgent or serious AMR threats. Others, such as group A and B Streptococci, are classified as concerning threats. Glycoconjugate vaccines have been demonstrated to be an efficacious and cost-effective measure to combat infections against Haemophilus influenzae, Neisseria meningitis, Streptococcus pneumoniae, and, more recently, Salmonella typhi. Recent times have seen enormous progress in methodologies for the assembly of complex glycans and glycoconjugates, with developments in synthetic, chemoenzymatic, and glycoengineering methodologies. This review analyzes the advancement of glycoconjugate vaccines based on synthetic carbohydrates to improve existing vaccines and identify novel candidates to combat AMR. Through this literature survey we built an overview of structure-immunogenicity relationships from available data and identify gaps and areas for further research to better exploit the peculiar role of carbohydrates as vaccine targets and create the next generation of synthetic carbohydrate-based vaccines.
Collapse
Affiliation(s)
| | - Kitt Emilie Østerlid
- Leiden Institute of Chemistry, Leiden University, 2300 RA Leiden, The Netherlands
| | - Dung-Yeh Wu
- Leiden Institute of Chemistry, Leiden University, 2300 RA Leiden, The Netherlands
| | | | | | - Jeroen Codée
- Leiden Institute of Chemistry, Leiden University, 2300 RA Leiden, The Netherlands
| | | |
Collapse
|
3
|
Berni F, Kalfopoulou E, Gimeno Cardells AM, Carboni F, van der Es D, Romero-Saavedra F, Laverde D, Miklic K, Malic S, Rovis TL, Jonjic S, Ali S, Overkleeft HS, Hokke CH, van Diepen A, Adamo R, Jiménez-Barbero J, van der Marel GA, Huebner J, Codée JDC. Epitope Recognition of a Monoclonal Antibody Raised against a Synthetic Glycerol Phosphate Based Teichoic Acid. ACS Chem Biol 2021; 16:1344-1349. [PMID: 34255482 PMCID: PMC8389533 DOI: 10.1021/acschembio.1c00422] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 07/08/2021] [Indexed: 11/29/2022]
Abstract
Glycerol phosphate (GroP)-based teichoic acids (TAs) are antigenic cell-wall components found in both enterococcus and staphylococcus species. Their immunogenicity has been explored using both native and synthetic structures, but no details have yet been reported on the structural basis of their interaction with antibodies. This work represents the first case study in which a monoclonal antibody, generated against a synthetic TA, was developed and employed for molecular-level binding analysis using TA microarrays, ELISA, SPR-analyses, and STD-NMR spectroscopy. Our findings show that the number and the chirality of the GroP residues are crucial for interaction and that the sugar appendage contributes to the presentation of the backbone to the binding site of the antibody.
Collapse
Affiliation(s)
- Francesca Berni
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Ermioni Kalfopoulou
- Division
of Pediatric Infectious Diseases, Dr. von Hauner Children’s
Hospital, Ludwig-Maximilians-University, 80337 Munich, Germany
- Institute
for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany
| | - Ana M. Gimeno Cardells
- CIC
bioGUNE, Basque Research and Technology
Alliance (BRTA), Bizkaia
Technology Park, 48160 Derio, Spain
- Ikerbasque, Basque
Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Spain
| | - Filippo Carboni
- Research
and Development Centre, GlaxoSmithKline
(GSK), 53100 Siena, Italy
| | - Daan van der Es
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Felipe Romero-Saavedra
- Division
of Pediatric Infectious Diseases, Dr. von Hauner Children’s
Hospital, Ludwig-Maximilians-University, 80337 Munich, Germany
| | - Diana Laverde
- Division
of Pediatric Infectious Diseases, Dr. von Hauner Children’s
Hospital, Ludwig-Maximilians-University, 80337 Munich, Germany
| | - Karmela Miklic
- Centre
for Proteomics, Faculty of Medicine, University
of Rijeka, 51000 Rijeka, Croatia
| | - Suzana Malic
- Centre
for Proteomics, Faculty of Medicine, University
of Rijeka, 51000 Rijeka, Croatia
| | - Tihana L. Rovis
- Centre
for Proteomics, Faculty of Medicine, University
of Rijeka, 51000 Rijeka, Croatia
| | - Stipan Jonjic
- Centre
for Proteomics, Faculty of Medicine, University
of Rijeka, 51000 Rijeka, Croatia
| | - Sara Ali
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Herman S. Overkleeft
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Cornelis H. Hokke
- Department
of Parasitology, Leiden University Medical
Center, Albinusdreef
2, 2333 ZA Leiden, The Netherlands
| | - Angela van Diepen
- Department
of Parasitology, Leiden University Medical
Center, Albinusdreef
2, 2333 ZA Leiden, The Netherlands
| | - Roberto Adamo
- Research
and Development Centre, GlaxoSmithKline
(GSK), 53100 Siena, Italy
| | - Jesús Jiménez-Barbero
- CIC
bioGUNE, Basque Research and Technology
Alliance (BRTA), Bizkaia
Technology Park, 48160 Derio, Spain
- Ikerbasque, Basque
Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Spain
| | | | - Johannes Huebner
- Division
of Pediatric Infectious Diseases, Dr. von Hauner Children’s
Hospital, Ludwig-Maximilians-University, 80337 Munich, Germany
| | - Jeroen D. C. Codée
- Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| |
Collapse
|
4
|
Harvey MR, Chiodo F, Noest W, Hokke CH, van der Marel GA, Codée JD. Synthesis and Antibody Binding Studies of Schistosome-Derived Oligo-α-(1-2)-l-Fucosides. Molecules 2021; 26:2246. [PMID: 33924587 PMCID: PMC8068878 DOI: 10.3390/molecules26082246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 04/08/2021] [Accepted: 04/08/2021] [Indexed: 11/30/2022] Open
Abstract
Schistosomiasis is caused by blood-dwelling parasitic trematodes of the genus Schistosoma and is classified by the WHO as the second most socioeconomically devastating parasitic disease, second only to malaria. Schistosoma expresses a complex array of glycans as part of glycoproteins and glycolipids that can be targeted by both the adaptive and the innate part of the immune system. Some of these glycans can be used for diagnostic purposes. A subgroup of schistosome glycans is decorated with unique α-(1-2)-fucosides and it has been shown that these often multi-fucosylated fragments are prime targets for antibodies generated during infection. Since these α-(1-2)-fucosides cannot be obtained in sufficient purity from biological sources, we set out to develop an effective route of synthesis towards α-(1-2)-oligofucosides of varying length. Here we describe the exploration of two different approaches, starting from either end of the fucose chains. The oligosaccharides have been attached to gold nanoparticles and used in an enzyme-linked immunosorbent assay ELISA and a microarray format to probe antibody binding. We show that binding to the oligofucosides of antibodies in sera of infected people depends on the length of the oligofucose chains, with the largest glycans showing most binding.
Collapse
Affiliation(s)
- Michael R. Harvey
- Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands; (M.R.H.); (F.C.); (W.N.); (G.A.v.d.M.)
| | - Fabrizio Chiodo
- Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands; (M.R.H.); (F.C.); (W.N.); (G.A.v.d.M.)
- Department of Parasitology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands;
| | - Wouter Noest
- Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands; (M.R.H.); (F.C.); (W.N.); (G.A.v.d.M.)
| | - Cornelis H. Hokke
- Department of Parasitology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands;
| | - Gijsbert A. van der Marel
- Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands; (M.R.H.); (F.C.); (W.N.); (G.A.v.d.M.)
| | - Jeroen D.C. Codée
- Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC Leiden, The Netherlands; (M.R.H.); (F.C.); (W.N.); (G.A.v.d.M.)
| |
Collapse
|